sumroeng chinnapan/
www.shutterstock.com
Drug delivery Innovation in I
nhaling drugs is not a new concept. Historical records and artefacts show examples of several ancient civilisations using inhaled vapours for a perceived medicinal benefit. In China, wars were fought to maintain the supply of opium, a Buddhist decoction used as a panacea for medical conditions. Another example can be seen in countries of the Middle East, where the smoking of shisha is still
inhalation
Blue and brown inhalers have become synonymous with asthma, but inhaling doses of medication is something we might see more of as drug developers look at inhalation as a strategy to treat more than just common respiratory diseases. Of course, developing inhalable drugs comes with its own set of challenges, both in the formulation process and in creating a human-centric device. Theresa Devereux speaks to Ben Forbes, professor of pharmaceutics at the Institute of Pharmaceutical Science at King’s College London; and Nélio Drumond, expert in patient-centric drug product design and associate director of manufacturing sciences at Takeda, to evaluate the state of play for inhaled drug delivery, as well as the barriers that must be overcome to make them commercially and medically viable.
associated with a reduction in stress and anxiety. Of course, with a comprehensive library of scientific literature to draw upon now, it’s well-known that both substances can cause harm. But advancements in medical science are also broadening the way medications can be delivered to the body, and there is a growing interest in how inhalable drugs might be used to treat conditions outside of common pulmonary diseases, like asthma, where they’re most often applied. Ben Forbes is professor of pharmaceutics at the Institute of Pharmaceutical Science at King’s College London, and he believes we’ll see more and more drugs taken through inhalation over the next few decades. “Going forward, a lot of the interest is around biologic drugs, and inhalation as a route for things that have to be injected at the moment,” he says. “There are also all the nucleic acid therapeutics and the follow on from the excitement generated by the success of some
16
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
